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 Q Could you tell our readers a little 
about your background & current 
position at the University of Glasgow?
I am a professor of molecular pharmacol-
ogy with a medium-sized research group. I 
started at Glasgow University as a techni-
cian and worked my way up to post-doc, and 
then through to lecturer, reader and profes-
sor. I have been here about 23 years, and just 
worked my way up from the beginning. I do 
everything – teaching, admin, running my 
own research group – a bit of everything.
 Q Your first degree was in agricultural 
botany; what made you shift focus 
& complete your PhD in pharmacology?
I did my PhD with Pfizer down in Sandwich 
(UK), which is when I got into drug discov-
ery. I was working on agricultural botany – I 
was interested in potatoes, and how to stop 
them getting contaminated with fungal dis-
ease when they are stored. I wanted to under-
stand how they get the fungal disease. I am 
from Ayrshire in Scotland, one of the biggest 
potato-growing regions, and I was heavily 
into that because of my local area, but it did 
not turn out that way. I actually tried to get 
a PhD, which I wrote myself, on the storage 
of potatoes, but I did not get the funding. I 
went to work for Pfizer on an antifungal com-
pound, but actually for humans. So I went 
from fungal disease into antifungals, into 
drug discovery. That is basically how I got 
here.
 Q What is the focus of your current 
research?
We work predominantly on phosphodiester-
ases. Most of my group works on cAMP-sig-
naling pathways and that means we work on 
many different diseases. We have got a funded 
project on chronic obstructive pulmonary 
disease (COPD) from the Medical Research 
Council, a schizophrenia-funded project, 
which is soon coming to its end, funded by 
Scottish Enterprise, and a couple of people 
working on prostate cancer, as well. These are 
all areas in which cAMP is involved. So we are 
pathway specific, rather than disease specific.
 Q What have you found with the 
schizophrenia project?
We have found a novel way to restore the 
levels of an important signal scaffold protein 
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called DISC1 that is involved in synaptic processes and 
brain development. This protein is downregulated in 
some forms of schizophrenia and bipolar disease. We 
can now interfere with a regulatory pathway that con-
trols protein levels of DISC1 and restore the deficit in 
patient derived cells.
 Q Your laboratory is a ‘world leader’ in 
using peptide array to map protein–protein 
interactions. Can you tell us about this?
We decided to make a novel PDE4 inhibitor, that didn’t 
target the active site – it targeted the area in the cell 
where the protein was anchored. So we started working 
on protein–protein interactions of phosphodiesterases, 
and how they are compartmentalized in cells by their 
anchoring domain. There are many isoforms and the 
only unique part is the anchoring domain. They essen-
tially do the same thing, but in different locations. To 
do that, we asked someone who knew about peptide 
array to map protein–protein interactions to help, and 
it was so successful we stopped doing things with yeast 
two-hybrid and with other molecular techniques. To 
map a protein–protein interaction over 25 amino acids, 
it takes a week using peptide array but over 6 months 
using yeast two-hybrid. We usually get the same results.
Basically, it is a robot that makes peptide on a cel-
lulose matrix. The peptides are covalently linked to the 
cellulose fibers; it anchors them so you can make pep-
tide libraries of any protein sequence on surfaces, and 
then you can put other proteins over the top, and see 
what peptides they bind to. We have got two different 
types of robots, and we are the only people in Scotland 
with the capability.
 Q What do you think are the biggest challenges 
in your research area at present?
Funding is very difficult at the moment. Our research 
is mostly translational, and we find it difficult get-
ting money for translational research. That is start-
ing to change. The British Heart Foundation has just 
announced its translational grant scheme, and the 
Medical Research Council has their own and there are 
various other ones. We do drug discovery, so it is quite 
a challenge getting the money in for that.
 Q Why is translational research lagging behind 
when it comes to funding?
Traditionally, the UK has funded basic research, and 
now the impact agenda is changing that – people need 
an output from their research; they need to show that 
they have made a discovery that is going to change 
something. With our translational research, we are 
better aligned to that, so things are starting to change, 
although it has been a slow process.
 Q How do you see this changing over the next 
10 years or so?
I think more and more of the funding bodies are real-
izing that there has to be some sort of impact from 
research, and it is got to be measurable. One of the 
things we can do is actually utilize our basic research, 
convert that into drug discovery and, hopefully, one 
day we might have a compound that is derived from 
our research. I do have a spin-off company that is try-
ing to take some of these things forward that we have 
done. That is Sannox Therapeutics, founded last year 
with the help of Glasgow University. Sannox intends 
to take some of the compounds and peptides that we 
have discovered that disrupt protein–protein inter-
actions and commercialise them. Basically, we need 
more information about how our compounds and pep-
tides work to make them attractive to pharmaceutical 
companies. It is very early days yet.
 Q What would you say has been your greatest 
achievement in your career to date?
In science terms, I was involved in the discovery that 
a protein called β-arrestin binds to phosphodiesterases 
and takes them to receptors to get rid of cAMP that 
has been produced as a result of this receptor activa-
tion – it was a receptor desensitization step. It was a 
paper with Bob Lefkowitz, who won the Nobel Prize 
recently for his work on receptors. So we actually pub-
lished with him on that discovery, which I think is my 
biggest achievement!
 Q You have various extra roles, including 
teaching & being a ‘Senate Assessor on Court’ at 
Glasgow University; can you tell us about these?
If you are a professor, you are on the Senate. Basically, 
all of the major decisions that happen at the Univer-
sity have to be put past the Senate for its approval. As 
there are so many professors, there are seven assessors 
selected by the Senate, who sit in on high-level man-
agement meetings to represent the Senate’s interest. 
Basically, we sit on University Court, major panels of 
recruitment, reviews for periodical change of subject 
areas, the financial and HR committees and we rep-
resent Senate’s interests in all these major committees. 
We read all the papers, get our heads round why all 
decisions have been made and challenge them if we 
do not think they are right. I was recently involved 
in the periodical review for Urban Studies – you are 
not allowed to be involved in reviews within your sub-
ject area – so I get to see how social science institutes 
work, which is completely different to ours and very 
interesting.
I also do lots of teaching, at all levels and a number of 
different courses, from basic protein structure to RNA 
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and DNA in the first year, right through to complex 
phosphodiesterase function in the final year. I do labo-
ratories, lectures, tutorials – I have approximately 65 
contact hours. I am also a course coordinator for the cell 
signaling option in the fourth year. I am in very early!
 Q You have recently been appointed to the 
Future Science OA editorial board; what are your 
thoughts on open access?
I think it is debatable. I think we will end up open 
access in the end. There is no point making a discov-
ery if people cannot find out about it. I think journals 
like Future Science OA are the way to go, and I think 
because they are easier to find, they will get more hits, 
become more popular and everyone else will have to 
follow suit.
 Q Finally, if you had unlimited resources, what 
would you do & why?
Peptide array can only really be used for protein–pro-
tein interactions that happen over a very short, contigu-
ous sequence, so if the proteins bind in regions formed 
by 3D structures from different parts of the protein 
then we cannot find it. Basically, there are certain types 
of protein–protein interaction ideal for peptide array. 
One of them is E3 ligase/substrate interactions in the 
ubiquitin cascade. They always bind onto short dock-
ing sequences before they trigger ubiquitination of the 
protein. So, what I would do, is take all of the orphan 
E3 ligases and set up yeast two-hybrid screens to find 
the substrates, and then I would find the binding sites 
using peptide array, and I would make competing pep-
tides and use those peptides to undergo drug discovery 
to find E3 ligase inhibitors for all the different classes 
of E3 ligase. There are hundreds and hundreds of 
them, so it would take a lot of time and money!
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